-
1
-
-
84860690425
-
Development of implants for sustained release of 5-fluorouracil using low molecular weight biodegradable polymers
-
Hanafy AF, El-Egaky AM, Mortada SA, Molokhia AM. Development of implants for sustained release of 5-fluorouracil using low molecular weight biodegradable polymers. Drug Discoveries and Therapeutics. 2009; 3: 287-295.
-
(2009)
Drug Discoveries and Therapeutics
, vol.3
, pp. 287-295
-
-
Hanafy, A.F.1
El-Egaky, A.M.2
Mortada, S.A.3
Molokhia, A.M.4
-
3
-
-
0022572450
-
Secondary malignant lesions of the heart and pericardium in neoplastic disease
-
Skhvatsabaja LV. Secondary malignant lesions of the heart and pericardium in neoplastic disease. Oncology. 1986; 43: 103-106.
-
(1986)
Oncology
, vol.43
, pp. 103-106
-
-
Skhvatsabaja, L.V.1
-
4
-
-
0034518827
-
Intrapericardial treatment of neoplastic pericardial effusions
-
Martinoni A, Cipolla CM, Civelli M, Cardinale D, Lamantia G, Colleoni M, DeBraud F, Susini G, Martinelli G, Goldhirsh A, Fiorentini C. Intrapericardial treatment of neoplastic pericardial effusions. Herz. 2000; 25: 787-793.
-
(2000)
Herz
, vol.25
, pp. 787-793
-
-
Martinoni, A.1
Cipolla, C.M.2
Civelli, M.3
Cardinale, D.4
Lamantia, G.5
Colleoni, M.6
DeBraud, F.7
Susini, G.8
Martinelli, G.9
Goldhirsh, A.10
Fiorentini, C.11
-
5
-
-
34247163206
-
Cardiac tamponade: an unusual, lifethreatening complication after transhiatal resection of the esophagus
-
Kats S, Nieuwenhuijzen GA, van Straten BH, Schonberger JP. Cardiac tamponade: an unusual, lifethreatening complication after transhiatal resection of the esophagus. Interactive Cardiovascular and Thoracic surgery. 2007; 6: 238-239.
-
(2007)
Interactive Cardiovascular and Thoracic surgery
, vol.6
, pp. 238-239
-
-
Kats, S.1
Nieuwenhuijzen, G.A.2
van Straten, B.H.3
Schonberger, J.P.4
-
6
-
-
23144467500
-
A case of cardiac tamponade following esophageal resection
-
Mizuguchi Y, Takeda S, Miyashita M, Ikezaki H, Nakajima Y, Akada S, Makino H, Futami R, Arai M, Sasajima K, Tajiri T, Tanaka K. A case of cardiac tamponade following esophageal resection. Journal of Anesthesia. 2005; 19: 249-251.
-
(2005)
Journal of Anesthesia
, vol.19
, pp. 249-251
-
-
Mizuguchi, Y.1
Takeda, S.2
Miyashita, M.3
Ikezaki, H.4
Nakajima, Y.5
Akada, S.6
Makino, H.7
Futami, R.8
Arai, M.9
Sasajima, K.10
Tajiri, T.11
Tanaka, K.12
-
7
-
-
56449083663
-
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
-
Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecologic Oncology. 2008; 111: 530-532.
-
(2008)
Gynecologic Oncology
, vol.111
, pp. 530-532
-
-
Hamilton, C.A.1
Maxwell, G.L.2
Chernofsky, M.R.3
Bernstein, S.A.4
Farley, J.H.5
Rose, G.S.6
-
8
-
-
84876204266
-
Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion
-
Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncology Reports. 2013; 29: 2332-2340.
-
(2013)
Oncology Reports
, vol.29
, pp. 2332-2340
-
-
Du, N.1
Li, X.2
Li, F.3
Zhao, H.4
Fan, Z.5
Ma, J.6
Fu, Y.7
Kang, H.8
-
9
-
-
33748475636
-
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
-
Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecologic Oncology. 2006; 102: 425-428.
-
(2006)
Gynecologic Oncology
, vol.102
, pp. 425-428
-
-
Numnum, T.M.1
Rocconi, R.P.2
Whitworth, J.3
Barnes, M.N.4
-
10
-
-
84979590540
-
Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin
-
Jiang L, Li P, Gong Z, Hu B, Ma J, Wang J, Chu H, Zhang L, Sun P, Chen J. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Research. 2016; 36: 1313-1318.
-
(2016)
Anticancer Research
, vol.36
, pp. 1313-1318
-
-
Jiang, L.1
Li, P.2
Gong, Z.3
Hu, B.4
Ma, J.5
Wang, J.6
Chu, H.7
Zhang, L.8
Sun, P.9
Chen, J.10
-
11
-
-
0017692936
-
Carcinomatous involvement of the pleura: an analysis of 96 patients
-
Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. The American Journal of Medicine. 1977; 63:695-702.
-
(1977)
The American Journal of Medicine
, vol.63
, pp. 695-702
-
-
Chernow, B.1
Sahn, S.A.2
-
12
-
-
0016195162
-
Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer
-
Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. American Journal of Obstetrics and Gynecology. 1974; 119: 991-994.
-
(1974)
American Journal of Obstetrics and Gynecology
, vol.119
, pp. 991-994
-
-
Feldman, G.B.1
Knapp, R.C.2
-
13
-
-
0013943030
-
Metastatic carcinoma of the pleura
-
Meyer PC. Metastatic carcinoma of the pleura. Thorax. 1966; 21: 437-443.
-
(1966)
Thorax
, vol.21
, pp. 437-443
-
-
Meyer, P.C.1
-
14
-
-
0015385809
-
The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma
-
Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Research. 1972; 32: 1663-1666.
-
(1972)
Cancer Research
, vol.32
, pp. 1663-1666
-
-
Feldman, G.B.1
Knapp, R.C.2
Order, S.E.3
Hellman, S.4
-
15
-
-
0021351361
-
Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis
-
Heuser LS, Taylor SH, Folkman J. Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. The Journal of Surgical Research. 1984; 36: 244-250.
-
(1984)
The Journal of Surgical Research
, vol.36
, pp. 244-250
-
-
Heuser, L.S.1
Taylor, S.H.2
Folkman, J.3
-
17
-
-
0017258035
-
Tumor angiogenesis activity in cells grown in tissue culture
-
Klagsbrun M, Knighton D, Folkman J. Tumor angiogenesis activity in cells grown in tissue culture. Cancer Research. 1976; 36: 110-114.
-
(1976)
Cancer Research
, vol.36
, pp. 110-114
-
-
Klagsbrun, M.1
Knighton, D.2
Folkman, J.3
-
18
-
-
62349103659
-
Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions
-
Zhou WB, Bai M, Jin Y. Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. International Journal of Tuberculosis and Lung Disease. 2009; 13: 381-386.
-
(2009)
International Journal of Tuberculosis and Lung Disease
, vol.13
, pp. 381-386
-
-
Zhou, W.B.1
Bai, M.2
Jin, Y.3
-
19
-
-
0031032073
-
Prognostic significance of vascular endothelial growth factor protein in nodenegative breast carcinoma
-
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T. Prognostic significance of vascular endothelial growth factor protein in nodenegative breast carcinoma. Journal of the National Cancer Institute. 1997; 89: 139-147.
-
(1997)
Journal of the National Cancer Institute
, vol.89
, pp. 139-147
-
-
Gasparini, G.1
Toi, M.2
Gion, M.3
Verderio, P.4
Dittadi, R.5
Hanatani, M.6
Matsubara, I.7
Vinante, O.8
Bonoldi, E.9
Boracchi, P.10
Gatti, C.11
Suzuki, H.12
Tominaga, T.13
-
20
-
-
0030969559
-
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
-
Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clinical Cancer Research. 1997; 3: 861-865.
-
(1997)
Clinical Cancer Research
, vol.3
, pp. 861-865
-
-
Fontanini, G.1
Vignati, S.2
Boldrini, L.3
Chine, S.4
Silvestri, V.5
Lucchi, M.6
Mussi, A.7
Angeletti, C.A.8
Bevilacqua, G.9
-
21
-
-
84962224315
-
Greater efficacy of chemotherapy plus bevacizumab compared to chemoand targeted therapy alone on non-small cell lung cancer patients with brain metastasis
-
Tang N, Guo J, Zhang Q, Wang Y, Wang Z. Greater efficacy of chemotherapy plus bevacizumab compared to chemoand targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget. 2016; 7: 3635-3644 doi: 10.18632/oncotarget.6184.
-
(2016)
Oncotarget
, vol.7
, pp. 3635-3644
-
-
Tang, N.1
Guo, J.2
Zhang, Q.3
Wang, Y.4
Wang, Z.5
-
22
-
-
70350435581
-
Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion
-
Ribeiro SC, Vargas FS, Antonangelo L, Marchi E, Genofre EH, Acencio MM, Teixeira LR. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology. 2009; 14: 1188-1193.
-
(2009)
Respirology
, vol.14
, pp. 1188-1193
-
-
Ribeiro, S.C.1
Vargas, F.S.2
Antonangelo, L.3
Marchi, E.4
Genofre, E.H.5
Acencio, M.M.6
Teixeira, L.R.7
-
23
-
-
0005419856
-
Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors
-
Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Research. 1998; 58: 2652-2660.
-
(1998)
Cancer Research
, vol.58
, pp. 2652-2660
-
-
Luo, J.C.1
Yamaguchi, S.2
Shinkai, A.3
Shitara, K.4
Shibuya, M.5
-
24
-
-
0345060442
-
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
-
Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clinical Cancer Research. 2003; 9: 5721-5728.
-
(2003)
Clinical Cancer Research
, vol.9
, pp. 5721-5728
-
-
Byrne, A.T.1
Ross, L.2
Holash, J.3
Nakanishi, M.4
Hu, L.5
Hofmann, J.I.6
Yancopoulos, G.D.7
Jaffe, R.B.8
-
25
-
-
0034145605
-
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
-
Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology. 2000; 16: 445-454.
-
(2000)
International Journal of Oncology
, vol.16
, pp. 445-454
-
-
Xu, L.1
Yoneda, J.2
Herrera, C.3
Wood, J.4
Killion, J.J.5
Fidler, I.J.6
-
26
-
-
0034091396
-
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence
-
Stoelcker B, Echtenacher B, Weich HA, Sztajer H, Hicklin DJ, Mannel DN. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. Journal of Interferon and Cytokine Research. 2000; 20: 511-517.
-
(2000)
Journal of Interferon and Cytokine Research
, vol.20
, pp. 511-517
-
-
Stoelcker, B.1
Echtenacher, B.2
Weich, H.A.3
Sztajer, H.4
Hicklin, D.J.5
Mannel, D.N.6
-
27
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research. 1997; 57: 4593-4599.
-
(1997)
Cancer Research
, vol.57
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
28
-
-
1842415455
-
Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer
-
Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Archives of Surgery. 1997; 132: 541-546.
-
(1997)
Archives of Surgery
, vol.132
, pp. 541-546
-
-
Takahashi, Y.1
Tucker, S.L.2
Kitadai, Y.3
Koura, A.N.4
Bucana, C.D.5
Cleary, K.R.6
Ellis, L.M.7
-
29
-
-
84943369737
-
Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review
-
Chen D, Zhang Y, Shi F, Li M, Zhu H, Kong L, Yu J. Sustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature review. OncoTargets and Therapy. 2015; 8: 2767-2770.
-
(2015)
OncoTargets and Therapy
, vol.8
, pp. 2767-2770
-
-
Chen, D.1
Zhang, Y.2
Shi, F.3
Li, M.4
Zhu, H.5
Kong, L.6
Yu, J.7
-
30
-
-
0036797258
-
Neoplastic pericardial effusion
-
Maisch B, Ristic AD, Pankuweit S, Neubauer A, Moll R. Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. European Heart Journal. 2002; 23: 1625-1631.
-
(2002)
Efficacy and safety of intrapericardial treatment with cisplatin. European Heart Journal
, vol.23
, pp. 1625-1631
-
-
Maisch, B.1
Ristic, A.D.2
Pankuweit, S.3
Neubauer, A.4
Moll, R.5
-
31
-
-
76749102922
-
Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade
-
Oida T, Mimatsu K, Kano H, Kawasaki A, Kuboi Y, Fukino N, Amano S. Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade. World Journal of Gastroenterology. 2010; 16: 740-744.
-
(2010)
World Journal of Gastroenterology
, vol.16
, pp. 740-744
-
-
Oida, T.1
Mimatsu, K.2
Kano, H.3
Kawasaki, A.4
Kuboi, Y.5
Fukino, N.6
Amano, S.7
-
32
-
-
84937117699
-
BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer
-
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology. 2015; 33: 2197-2204.
-
(2015)
Journal of Clinical Oncology
, vol.33
, pp. 2197-2204
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
Liu, X.4
Zhu, Y.5
Lu, S.6
Feng, J.7
He, J.8
Han, B.9
Wang, J.10
Jiang, G.11
Hu, C.12
-
33
-
-
84911381185
-
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
-
Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews. 2014; 9: CD011230.
-
(2014)
Cochrane Database of Systematic Reviews
, vol.9
-
-
Moja, L.1
Lucenteforte, E.2
Kwag, K.H.3
Bertele, V.4
Campomori, A.5
Chakravarthy, U.6
D'Amico, R.7
Dickersin, K.8
Kodjikian, L.9
Lindsley, K.10
Loke, Y.11
Maguire, M.12
Martin, D.F.13
-
34
-
-
84926327497
-
The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion
-
Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion. Indian Journal of Cancer. 2014; 51: e82-85.
-
(2014)
Indian Journal of Cancer
, vol.51
, pp. e82-e85
-
-
Chen, D.1
Li, X.2
Zhao, H.3
Fu, Y.4
Yao, F.5
Hu, J.6
Du, N.7
|